Stock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA

Stock Track

Apr 10

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) saw its shares surge 8.14% during intraday trading on Friday, following a significant regulatory development for one of its key investigational products.

The company announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px, also known as Pixclara. This is a positron emission tomography (PET) imaging agent designed for the characterization of recurrent or progressive glioma, a form of brain cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for its review.

This regulatory milestone is viewed positively by the market as it addresses a critical unmet medical need. TLX101-Px has previously been granted both Orphan Drug and Fast Track designations by the FDA, which are intended to facilitate the development and review of drugs for serious conditions. The company's FY 2026 financial guidance explicitly states it does not include any revenue contribution from TLX101-Px, indicating that the stock movement is driven by the future potential and reduced regulatory risk associated with this application acceptance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1194270889"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194270889\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194270889?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194270889","market":"hk","top_or_hot":-1,"title":"Stock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA","media":"Stock Track","content":"<p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) saw its shares surge 8.14% during intraday trading on Friday, following a significant regulatory development for one of its key investigational products.</p><p>The company announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px, also known as Pixclara. This is a positron emission tomography (PET) imaging agent designed for the characterization of recurrent or progressive glioma, a form of brain cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for its review.</p><p>This regulatory milestone is viewed positively by the market as it addresses a critical unmet medical need. TLX101-Px has previously been granted both Orphan Drug and Fast Track designations by the FDA, which are intended to facilitate the development and review of drugs for serious conditions. The company's FY 2026 financial guidance explicitly states it does not include any revenue contribution from TLX101-Px, indicating that the stock movement is driven by the future potential and reduced regulatory risk associated with this application acceptance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-10 08:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) saw its shares surge 8.14% during intraday trading on Friday, following a significant regulatory development for one of its key investigational products.</p><p>The company announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px, also known as Pixclara. This is a positron emission tomography (PET) imaging agent designed for the characterization of recurrent or progressive glioma, a form of brain cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for its review.</p><p>This regulatory milestone is viewed positively by the market as it addresses a critical unmet medical need. TLX101-Px has previously been granted both Orphan Drug and Fast Track designations by the FDA, which are intended to facilitate the development and review of drugs for serious conditions. The company's FY 2026 financial guidance explicitly states it does not include any revenue contribution from TLX101-Px, indicating that the stock movement is driven by the future potential and reduced regulatory risk associated with this application acceptance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1194270889","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194270889","pubTimestamp":1775779363,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) saw its shares surge 8.14% during intraday trading on Friday, following a significant regulatory development for one of its key investigational...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"个股追踪|Telix制药盘中大涨8.14%因FDA受理脑癌显像剂NDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1},"content_text":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) saw its shares surge 8.14% during intraday trading on Friday, following a significant regulatory development for one of its key investigational products.The company announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px, also known as Pixclara. This is a positron emission tomography (PET) imaging agent designed for the characterization of recurrent or progressive glioma, a form of brain cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for its review.This regulatory milestone is viewed positively by the market as it addresses a critical unmet medical need. TLX101-Px has previously been granted both Orphan Drug and Fast Track designations by the FDA, which are intended to facilitate the development and review of drugs for serious conditions. The company's FY 2026 financial guidance explicitly states it does not include any revenue contribution from TLX101-Px, indicating that the stock movement is driven by the future potential and reduced regulatory risk associated with this application acceptance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}